[천지일보=홍보영 기자] GC Green Cross begins shipping’Hunterase ICV (intracerebroventricular)’.
GC Green Cross announced on the 3rd that it will ship the world’s first severe hunter syndrome treatment’Hunterase ICV’ (product name: Whitarase) to Japan.
It is an analysis that the market penetration has entered the visible range as the initial supply of goods has been made in a month or so after acquiring the Japanese item license in January.
Hunterase ICV is a treatment in which a device is inserted into the head and the drug is administered directly to the ventricle. The existing intravenous formulation of drugs could not pass through the cerebral vascular barrier (BBB) and thus could not reach the’cerebral parenchyma’.
As the Japan Ministry of Health, Labor and Welfare (MHLW) is currently in the process of listing insurance drug prices, once the drug price is confirmed and notified, it is expected to be officially released and prescribed in the actual medical field. It is known that the Japanese medical community and patient associations also have high expectations for the efficacy and safety of Hunterase ICV, which has been clinically confirmed. The company expects that the sales of Hunterase ICV will be in full swing in Japan as early as two quarters.
Earlier last month, IV-based Hunterase (product name: Hai Rui Tsu) was also shipped to China for the first time. In China, in September of last year, Hunterase was approved as the first treatment for Hunter syndrome in China, and is currently undergoing drug price listing procedures.
An official from GC Green Cross said, “The process is rapidly progressing so that Hunterase can be used by patients as a new treatment option.
On the other hand, Hunter’s syndrome is a rare congenital disease in which skeletal abnormalities and decreased intelligence occur due to deficiency of IDS (Iduronate-2-sulfatase) enzyme. In general, it is known that it occurs at the rate of 1 in 100,000 to 150,000 male children. Severe patients with central nerve damage account for 70% of all Hunter syndrome patients.
‘;
Copyright © Cheonji Ilbo-Unauthorized reproduction and redistribution of the press release of hope for a new era is prohibited